Privia Health Group (NASDAQ:PRVA) Price Target Raised to $31.00

Privia Health Group (NASDAQ:PRVA) had its price target lifted by Citizens Jmp from $30.00 to $31.00 in a research note published on Friday,Benzinga reports. Citizens Jmp currently has a market outperform rating on the stock.

A number of other equities research analysts have also weighed in on the company. JMP Securities raised their price objective on Privia Health Group from $29.00 to $30.00 and gave the company a “market outperform” rating in a research note on Friday, August 29th. Citigroup reiterated an “outperform” rating on shares of Privia Health Group in a research note on Friday, August 29th. Piper Sandler dropped their price target on shares of Privia Health Group from $36.00 to $35.00 and set an “overweight” rating for the company in a research note on Monday, August 11th. Stephens reaffirmed an “overweight” rating and issued a $32.00 price target on shares of Privia Health Group in a report on Wednesday, September 24th. Finally, Zacks Research raised shares of Privia Health Group from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 19th. Twelve equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $29.58.

Privia Health Group Stock Performance

Shares of PRVA stock traded down $0.02 on Friday, hitting $23.41. The stock had a trading volume of 1,074,552 shares, compared to its average volume of 847,292. The stock’s 50 day moving average is $24.15 and its 200-day moving average is $22.76. The firm has a market capitalization of $2.88 billion, a price-to-earnings ratio of 180.09, a P/E/G ratio of 3.32 and a beta of 0.83. Privia Health Group has a 52-week low of $18.77 and a 52-week high of $26.51.

Privia Health Group (NASDAQ:PRVA) last issued its quarterly earnings data on Tuesday, June 7th. The company reported $0.10 EPS for the quarter. The firm had revenue of $213.61 million for the quarter. Privia Health Group had a net margin of 0.89% and a return on equity of 2.52%. Equities analysts expect that Privia Health Group will post 0.14 earnings per share for the current year.

Institutional Trading of Privia Health Group

Institutional investors have recently made changes to their positions in the stock. Van Berkom & Associates Inc. bought a new position in shares of Privia Health Group in the first quarter valued at approximately $45,207,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Privia Health Group by 180.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,633,040 shares of the company’s stock worth $59,112,000 after purchasing an additional 1,693,870 shares during the period. Nuveen LLC acquired a new position in shares of Privia Health Group during the 1st quarter valued at $26,899,000. Vanguard Group Inc. raised its stake in shares of Privia Health Group by 5.3% in the 3rd quarter. Vanguard Group Inc. now owns 12,098,933 shares of the company’s stock worth $301,263,000 after buying an additional 607,447 shares in the last quarter. Finally, Royce & Associates LP bought a new stake in shares of Privia Health Group in the 1st quarter worth $6,818,000. 94.48% of the stock is owned by institutional investors and hedge funds.

About Privia Health Group

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.